Yarrow Bioscience (NASDAQ:YARW) Sees Significant Increase in Short Interest

Yarrow Bioscience (NASDAQ:YARW) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 56,499 shares, a growth of 190.8% from the August 15th total of 19,427 shares. Based on an average daily volume of 46,917 shares, the days-to-cover ratio is currently 1.2 days. Approximately 2.2% of the company’s shares are short sold.

Yarrow Bioscience Stock Performance

Shares of YARW traded down $1.04 on Monday, hitting $25.97. 50,208 shares of the stock traded hands, compared to its average volume of 22,602. Yarrow Bioscience has a 1 year low of $14.68 and a 1 year high of $46.95. The company has a market capitalization of $69.34 million, a price-to-earnings ratio of -1.77 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million. Yarrow Bioscience had a negative return on equity of 84.40% and a negative net margin of 4,726.21%.

Yarrow Bioscience Dividend Announcement

The business also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were issued a dividend of $19.00 per share.

Hedge Funds Weigh In On Yarrow Bioscience

Large investors have recently modified their holdings of the stock. Two Sigma Securities LLC acquired a new stake in shares of Yarrow Bioscience during the 2nd quarter valued at approximately $26,000. BlackRock Inc. acquired a new stake in shares of Yarrow Bioscience during the second quarter worth approximately $29,000. T3 Companies LLC acquired a new stake in shares of Yarrow Bioscience during the 4th quarter valued at about $548,000. Nantahala Capital Management LLC bought a new position in Yarrow Bioscience during the second quarter valued at approximately $1,301,400,000. Finally, ADAR1 Capital Management LLC increased its stake in shares of Yarrow Bioscience by 319.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock worth $636,000 after purchasing an additional 810,108 shares during the last quarter. Institutional investors own 83.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on YARW. BTIG Research initiated coverage on Yarrow Bioscience in a research note on Monday, August 3rd. They set a “buy” rating and a $58.00 price objective for the company. Wall Street Zen raised Yarrow Bioscience to a “hold” rating in a report on Saturday, August 22nd. Finally, TD Cowen started coverage on Yarrow Bioscience in a report on Tuesday, July 28th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $58.00.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.